MARKHAM, ON, Aug. 23 /CNW/ - Cytochroma Inc. announced today that Mr.
Gordon Ngan has joined Cytochroma's management team as Executive Director,
Corporate Development. Mr. Ngan will be responsible for coordinating corporate
finance and related investor activities, as well as securing corporate
partnerships with firms focused on the chronic kidney disease (CKD) market.
Mr. Ngan brings to Cytochroma more than 10 years of finance, capital
markets, investor relations, and business development experience. Most
recently, Mr. Ngan was Associate Analyst, Biotechnology and Pharmaceuticals
for the Equity Research group at National Bank Financial where he was involved
in identifying and researching promising healthcare companies. Previous to his
experiences on the sellside, he held a number of industry roles at BioChem
Pharma and Shire Pharmaceuticals Group plc, including Head of North American
Investor Relations, and then Global Head of Investor Relations, followed by a
role in business development at Shire's UK headquarters. In this latter role,
Mr. Ngan worked on a number of successful partnership deals in the renal,
hematology, and CNS fields.
"We are pleased to welcome Gordon to the management team at Cytochroma,"
said Charles W. Bishop, PhD, President and CEO. "We intend to further develop
Cytochroma's capital markets and investor strategy and Gordon brings valuable
experience and a unique perspective that will play a critical role in
achieving this goal."
"Cytochroma has an experienced management team which has built a
remarkable portfolio of renal products addressing clear areas of unmet medical
need and has established strong relationships with key opinion leaders in the
scientific and clinical community. I am delighted to join Cytochroma at this
exciting stage of the Company's development," stated Mr. Ngan. "I look forward
to working with investors and corporate partners to rapidly grow the company
and advance its products."
About Cytochroma Inc.
Cytochroma (www.cytochroma.com) is a specialty pharmaceutical company
engaged in the development and commercialization of proprietary products to
treat and prevent the clinical consequences of Vitamin D insufficiency. The
Company has an advanced portfolio of new therapies for Vitamin D insufficiency
and secondary hyperparathyroidism associated with CKD. In addition, the
Company is developing novel therapies to treat hyperproliferative disorders,
such as cancer and psoriasis, and hyperphosphatemia.
For further information:
For further information: Eric J. Messner, Vice President, Commercial
Operations, (905) 479-5306 ext. 338, firstname.lastname@example.org